We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NUTR:NASDAQNusatrip Incorporated Analysis

Data as of 2026-06-09 - not real-time

$9.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

NUTR trades flat at $9 with the 20‑day and 50‑day SMAs locked at the same level, signaling a lack of directional bias. The RSI is perched in the extreme‑overbought zone, while the MACD histogram has turned negative, giving the technical picture a bearish tilt. Volume has been essentially nonexistent, and the stock sits at a hard resistance of $9 with no clear support, underscoring liquidity concerns. Market sentiment is exuberant, as reflected by an “Extreme Greed” reading on the Fear‑Greed Index, which is at odds with the underlying fundamentals.
Fundamentally, the company posts negligible revenue growth, razor‑thin gross margins that are effectively 100 % due to accounting quirks, and operating and net losses that translate into negative EPS and cash‑flow deficits. The balance sheet is strained with a debt‑to‑equity near 2 × and a price‑to‑book that is almost 14 times, while the price‑to‑sales exceeds 70 ×, indicating severe overvaluation. A recent Nasdaq delinquency notice adds regulatory headwinds, and the travel‑services sector remains cyclical and vulnerable to regional economic swings. Given the combination of technical weakness, financial distress, and heightened regulatory risk, the near‑term outlook is bearish, though a longer‑term turnaround could hinge on restructuring and a rebound in Southeast Asian travel demand.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Nasdaq delinquency notice raises immediate compliance risk
  • Technical indicators show overbought RSI and bearish MACD
  • Liquidity is virtually nonexistent with zero trading volume

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential restructuring of debt could improve balance sheet
  • Regional travel demand may recover post‑pandemic
  • Current valuation may compress if sentiment shifts

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • Long‑term upside depends on successful turnaround of operations
  • Travel sector cyclicality could provide growth opportunities
  • High price multiples make entry costly without clear earnings

Key Metrics & Analysis

Financial Health

Revenue Growth343.20%
Profit Margin-37.44%
ROE-37.56%
ROA-6.30%
Debt/Equity1.93
P/B Ratio13.9
Op. Cash Flow$-14855793
Free Cash Flow$-8682307

Technical Analysis

TrendNeutral
RSI79.4
Support$0.00
Resistance$9.00
MA 20$9.00
MA 50$9.00
MA 200$8.49
MACDBearish
VolumeStable
Fear & Greed Index87.64

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta-0.01
0
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.